Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Director William R. Ringo sold 1,800 shares of Five Prime Therapeutics stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $40.26, for a total transaction of $72,468.00. Following the sale, the director now owns 1,200 shares of the company’s stock, valued at $48,312. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) opened at 38.19 on Wednesday. The firm has a 50-day moving average price of $33.83 and a 200 day moving average price of $31.79. The stock’s market cap is $1.07 billion. Five Prime Therapeutics, Inc. has a 52 week low of $25.97 and a 52 week high of $60.98.

Five Prime Therapeutics (NASDAQ:FPRX) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.43). The company had revenue of $7.80 million during the quarter, compared to the consensus estimate of $8.32 million. Five Prime Therapeutics had a negative net margin of 356.39% and a negative return on equity of 31.78%. The business’s revenue was down 16.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.49) earnings per share. On average, analysts forecast that Five Prime Therapeutics, Inc. will post ($5.29) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/04/five-prime-therapeutics-inc-fprx-director-william-r-ringo-sells-1800-shares-of-stock.html.

A number of research firms have commented on FPRX. Jefferies Group LLC reissued a “buy” rating and issued a $52.00 price target on shares of Five Prime Therapeutics in a research note on Tuesday, September 12th. BMO Capital Markets restated a “hold” rating and set a $39.00 price objective on shares of Five Prime Therapeutics in a research report on Friday, September 22nd. Royal Bank Of Canada started coverage on shares of Five Prime Therapeutics in a research report on Thursday, September 14th. They set an “outperform” rating and a $41.00 price objective on the stock. ValuEngine raised shares of Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, BidaskClub downgraded shares of Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $54.86.

Several institutional investors have recently modified their holdings of the company. FMR LLC grew its position in shares of Five Prime Therapeutics by 1.8% during the first quarter. FMR LLC now owns 4,343,501 shares of the biotechnology company’s stock valued at $157,017,000 after purchasing an additional 77,381 shares in the last quarter. State Street Corp increased its holdings in shares of Five Prime Therapeutics by 8.4% in the second quarter. State Street Corp now owns 1,354,597 shares of the biotechnology company’s stock worth $40,782,000 after purchasing an additional 105,077 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Five Prime Therapeutics by 11.0% in the first quarter. Dimensional Fund Advisors LP now owns 933,410 shares of the biotechnology company’s stock worth $33,743,000 after buying an additional 92,338 shares in the last quarter. BB Biotech AG lifted its position in shares of Five Prime Therapeutics by 6.9% in the second quarter. BB Biotech AG now owns 777,500 shares of the biotechnology company’s stock worth $23,411,000 after buying an additional 50,000 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its position in shares of Five Prime Therapeutics by 28.9% in the second quarter. Victory Capital Management Inc. now owns 666,440 shares of the biotechnology company’s stock worth $20,066,000 after buying an additional 149,340 shares in the last quarter. Hedge funds and other institutional investors own 84.05% of the company’s stock.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Insider Buying and Selling by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Stock Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related stocks with our FREE daily email newsletter.